Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
05/2007
05/01/2007US7211254 Nucleotide sequences coding interleukin-9 induced calcium activated chloride channel for use in identifying modulators for treatment and prevention of asthma, allergies and respiratory system disorders
05/01/2007US7211251 Antibodies to transferrin receptor-like proteins
05/01/2007US7211248 Controlling lipid metabolism; injecting a solution of Dna, Rna gene using gas microbubbles using ultrasonic frequency; gene expression
05/01/2007US7211246 Compositions comprising oestrone-3-0-sulphamate and trail (TNF-related apoptosis inducing ligand)
05/01/2007CA2431397C Self emulsifying lipid matrix (selm)
05/01/2007CA2350794C Use of agonists of glucocorticosteroid receptors and/or mineral corticosteroid receptors, especially corticosteroids to treat addictions
05/01/2007CA2340545C Chelate compound-containing antibacterial agent for helicobacter pylori
05/01/2007CA2326756C Pharmaceutical compositions containing compounds with activity for the enhancement of absorption of active ingredients
05/01/2007CA2320706C 20-hete antagonists and agonists
05/01/2007CA2306963C Novel 3,6-hemiketals from the class of 9a-azalides
05/01/2007CA2305458C Nonsteroidal (hetero) cyclically-substituted acylanilides with mixed gestagenic and androgenic activity
05/01/2007CA2301590C 2-aminopyridines as inhibitors of cyclooxygenase-2
05/01/2007CA2290893C Magnesium omeprazole
05/01/2007CA2284133C Novel cell line and screening method with the use of the same
05/01/2007CA2283587C Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with n- or c-linked imidazoles
05/01/2007CA2269594C Use of complexes for the preparation of compositions for the treatment of sensitive skin, preparation process and hypoallergenic compositions
05/01/2007CA2268434C Mycophenolic bisphosphonate derivatives and their preparation from tetraphosphonate bicyclic trisanhydrides
05/01/2007CA2254060C Effervescent bisphosphonate formulation
05/01/2007CA2244836C Benzoheterocyclic derivatives as antidiabetic and antiobesity agents
05/01/2007CA2244357C A novel pharmaceutical composition for inhalation containing cr 2039 (andolast)
05/01/2007CA2227205C Treatment and prevention of neoplasms with salts of aminoimidazole carboxamide and 5-amino or substituted amino 1,2,3-triazoles
05/01/2007CA2226934C Ipratropium bromide enantiomer with a prolonged duration of action
05/01/2007CA2214343C Liquid aqueous pharmaceutical compositions comprising sodium alginate and potassium bicarbonate
05/01/2007CA2206748C Salts of ethyl 3-(2-(4-(4-(amino-imino-methyl)phenyl)-4-methyl-2,5-dioxoimidazolidin-1-yl)acetylamino)-3-phenylpropionate
05/01/2007CA2192813C Methods of inducing gene expression by ionizing radiation
05/01/2007CA2192215C Recombinant aav genome encoding immunodeficiency virus protein
05/01/2007CA2191440C Treatment and prevention of helicobacter infection
05/01/2007CA2189524C Aminomethyl-2,3,8,9-tetrahydro-7h-1,4-dioxino-[2,3e]indol-8-ones and derivatives
05/01/2007CA2188267C Use of tetrahydropteridine derivatives as no-synthase inhibitors
05/01/2007CA2185394C Biotinderivate
05/01/2007CA2180447C Preparation of bone for transplantation
05/01/2007CA2176960C Novel carbamate compounds and processes for preparing the same
05/01/2007CA2174116C Use of .alpha.-1,4-glucan lyase for preparation of 1,5-d-anhydrofructose
05/01/2007CA2162630C Sulfonamides
05/01/2007CA2155493C Carbapenem derivatives containing a bicyclic ketone substituent and their use as anti-infectives
05/01/2007CA2153068C Enhancer sequence for modulating expression in epithelial cells
05/01/2007CA2148632C Topical medicament having cicatrizing activity
05/01/2007CA2143636C Derivatives of valproic and 2-valproenoic acid amides and use as anticonvulsants
05/01/2007CA2138675C Catecholamine surrogates useful as .beta.3 agonists
05/01/2007CA2129773C Aromatic carboxylic acid derivatives
04/2007
04/30/2007CA2554874A1 Methods of reducing alcohol-induced dose dumping for hydromorphone sustained release oral dosage forms
04/30/2007CA2554701A1 Methods of reducing alcohol-induced dose dumping for opioid sustained release oral dosage forms
04/30/2007CA2554698A1 Methods of reducing alcohol-induced dose dumping for hydrocodone sustained release oral dosage forms
04/30/2007CA2554697A1 Methods of reducing alcohol-induced dose dumping for morphine sustained release oral dosage forms
04/30/2007CA2554693A1 Methods of reducing alcohol-induced dose dumping for oxymorphone sustained release oral dosage forms
04/30/2007CA2554684A1 Methods of reducing alcohol-induced dose dumping for oxycodone sustained release oral dosage forms
04/27/2007CA2564456A1 Methods and compositions for epilation
04/27/2007CA2564065A1 Methods and compositions for epilation
04/26/2007WO2007048121A2 Methods of preparing targeted immunoliposomes
04/26/2007WO2007048088A2 Method of inhibiting flt3 kinase
04/26/2007WO2007048080A2 Stable pharmaceutical formulations containing escitalopram and bupropion
04/26/2007WO2007048070A2 Pyrrolo-pyridine derivatives for the treatment of cancer diseases
04/26/2007WO2007048059A2 Method of treating clostridium difficile-associated diarrhea
04/26/2007WO2007048046A2 Sirna silencing of filovirus gene expression
04/26/2007WO2007048042A2 Small molecule inhibitors of hiv-1 capsid assembly
04/26/2007WO2007048034A2 Use of androgens for the treatment of parkinson' s disease
04/26/2007WO2007048027A2 Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent
04/26/2007WO2007048004A2 Compounds for enhancing hypoxia inducible factor activity and methods of use
04/26/2007WO2007048002A2 Camptothecin derivatives as chemoradiosensitizing agents
04/26/2007WO2007047991A1 Tetrahydroisoquinoline as lxr modulators
04/26/2007WO2007047935A1 Compositions containing opioid antagonists
04/26/2007WO2007047919A2 Treatment of restenosis and stenosis with dasatinib
04/26/2007WO2007047881A2 Method for treating neuropathic pain
04/26/2007WO2007047880A2 Compositions for lowering serum cholesterol and/or triglycerides
04/26/2007WO2007047863A2 Crystals of laquinimod sodium, and process for the manufacture thereof
04/26/2007WO2007047839A1 Method for treating pain
04/26/2007WO2007047837A2 (-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses for treating alcohol-related disorders
04/26/2007WO2007047820A1 Method for treating pain
04/26/2007WO2007047811A2 Improved reproductive management
04/26/2007WO2007047793A2 Cyclopentenol nucleoside compounds, intermediates for their synthesis and methods of treating viral infections
04/26/2007WO2007047775A1 Indole derivatives as histamine 3 receptor inhibitors for the treatment of cognitive and sleep disorders, obesity and other cns disorders
04/26/2007WO2007047752A1 Method for treating pain
04/26/2007WO2007047737A1 Cb-1 modulating compounds and their use
04/26/2007WO2007047725A2 Methods for treating disorders associated with hyperlipidemia in a mammal
04/26/2007WO2007047724A2 Compositions for lowering serum cholesterol and/or triglycerides
04/26/2007WO2007047722A2 Methods for treating disorders associated with hyperlipidemia in a mammal
04/26/2007WO2007047698A2 Methods and compositions for the treatment of neuropsychiatric and addictive disorders
04/26/2007WO2007047676A1 Pyrazole derivatives, compositions containing such compounds and methods of use
04/26/2007WO2007047646A2 Substituted dihydro-isoindolones useful in treating kinase disorders
04/26/2007WO2007047626A1 Combination treatment with anecortave acetate and bevacizumab or ranibizumab for pathologic ocular angiogenesis
04/26/2007WO2007047625A2 Triazole derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
04/26/2007WO2007047623A2 Methods of inhibiting cell growth and methods of enhancing radiation responses
04/26/2007WO2007047607A2 Ocular therapy using glucocorticoid derivatives selectively penetrating posterior segment tissues
04/26/2007WO2007047596A1 Methods for reducing food intake and decreasing appetite in animals
04/26/2007WO2007047591A2 Cetp inhibitors
04/26/2007WO2007047582A2 Porphyrin compounds for enhancing mitochondrial function
04/26/2007WO2007047577A2 Use of calcitonin-related peptide (cgrp) antagonists or release inhibitors for the treatment of sleep-related breathing disorders
04/26/2007WO2007047576A1 Pharmacological treatments for sleep disorders
04/26/2007WO2007047575A2 Pharmacological treatments for sleep-related breathing disorders
04/26/2007WO2007047553A2 Methods and compositions for treatment of prostate intraepithelial neoplasia
04/26/2007WO2007047539A2 Localized delivery to the lymphatic system
04/26/2007WO2007047496A2 Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
04/26/2007WO2007047492A2 Increasing thymic output in hiv-negative patients with antiretrovirals
04/26/2007WO2007047486A2 Hydroxy-oligocarboxylic esters: effects on nerve and use for cutaneous and mucocutaneous organs or sites
04/26/2007WO2007047474A2 Biphenyl derivatives as modulators of voltage gated ion channels
04/26/2007WO2007047473A2 Methods of administering rapamycin analogs with anti-inflammatories using medical devices
04/26/2007WO2007047432A1 Sulfonamide derivatives as modulators of ppar
04/26/2007WO2007047431A2 Sulfonyl-substituted aryl compounds as modulators of peroxisome proliferator activated receptors
04/26/2007WO2007047416A2 Compositions and methods of administering rapamycin analogs with paclitaxel using medical devices
04/26/2007WO2007047406A2 Liquid pharmaceutical compositions of nimodipine